Bortezomib-d8

• CAT Number: S000062
• Molecular Formula: C19H17D8BN4O4
• Molecular Weight: 392.29
• Purity: ≥95%
• Target: NF-κB
• IUPAC Name: [(1R)-3-methyl-1-[[(2R)-2,3,3-trideuterio-3-(2,3,4,5,6-pentadeuteriophenyl)-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
• InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17+/m1/s1/i3D,4D,5D,6D,7D,11D2,15D
• InChIKey: GXJABQQUPOEUTA-PGWCMDPNSA-N
• SMILES: [2H]C1=C(C(=C(C(=C1[2H])[2H])C([2H])([2H])[C@]([2H])(C(=O)N[C@H](B(O)O)CC(C)C)NC(=O)C2=NC=CN=C2)[2H])[2H]

Bortezomib-d8 is a high-purity deuterated compound used in advanced pharmaceutical research. This isotopically labeled version of Bortezomib is essential for studies involving proteasome inhibitors, cancer therapeutics, pharmacokinetics, and metabolic pathways. Featuring eight deuterium atoms, it ensures precise and reliable analytical results. Its advanced formulation provides enhanced stability and consistency, making it suitable for various experimental setups. Ideal for oncology research and drug development, Bortezomib-d8 integrates seamlessly into existing protocols, offering a robust and cost-effective solution for high-precision scientific investigations.